Answers are grounded in this paper and cite their sources.
Background Siponimod (BAF312), a selective S1P 1 /S1P 5 agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P 1 /S1P 5 -dependent anti-inflammatory and pro-myelination effects on CNS-resident cells. Objective Generate preclinical evidence confirming siponimod's CNS penetration and activity. Methods Siponimod's CNS penetration and distribution was explored in rodents and non-human primates (NHPs) using: Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS), quantitative whole-body autoradiography (QWBA) using 14 C-radiolabeled siponimod or non-invasive single-photon emission CT (SPECT) with a validated 123 I-radiolabeled siponimod analog. Functional CNS activity was investigated by S1P 1 receptor quantification in brain homogenates. Results In mice/rats, siponimod treatments achieved dose-dependent efficacy and dose-proportional increase in drug blood levels, with mean brain/blood drug-exposure ratio ( Brain/Blood DER) of 6–7. Efficacy in rat brain tissues was revealed by a dose-dependent reduction in brain S1P 1 levels. QWBA distribution analysis in rats indicated that [ 14 C]siponimod related radioactivity could readily penetrate CNS, with particularly high uptakes in white matter of cerebellum, corpus callosum, and medulla oblongata versus lower exposures in other areas such as olfactory bulb. SPECT monitoring in NHPs revealed CNS distribution with a brain/blood DER of ∼6, as in rodents. Conclusion Findings demonstrate siponimod's CNS penetration and distribution across species, with high translational potential to human.
No takes yet. Share an insight, caveat, or question.
Bigaud et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: